A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14
ContributorsRentsch, Cyrill A; Thalmann, George N; Lucca, Ilaria; Kwiatkowski, Maciej; Wirth, Grégory Johann; Strebel, Räto T; Engeler, Daniel; Pedrazzini, Augusto; Hüttenbrink, Clemens; Schultze-Seemann, Wolfgang; Torpai, Raimund; Bubendorf, Lukas; Wicki, Andreas; Roth, Beat; Bosshard, Piet; Püschel, Heike; Boll, Daniel T; Hefermehl, Lukas; Roghmann, Florian; Gierth, Michael; Ribi, Karin; Schäfer, Simon; Hayoz, Stefanie
Published inEuropean urology oncology, vol. 5, no. 2, p. 195-202
Publication date2022-04
First online date2022-01-07
Abstract
Keywords
- Bacillus Calmette-Guérin
- Genomically modified organism
- Non–muscle-invasive bladder cancer
- Phase 2 single-arm trial
- VPM1002BC
Affiliation entities
Research groups
Citation (ISO format)
RENTSCH, Cyrill A et al. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. In: European urology oncology, 2022, vol. 5, n° 2, p. 195–202. doi: 10.1016/j.euo.2021.12.006
Main files (1)
Article (Published version)
Identifiers
- PID : unige:161353
- DOI : 10.1016/j.euo.2021.12.006
- PMID : 35012889
Journal ISSN2588-9311
